SYNC-T prostate cancer treatment shows encouraging long-term survival as LEGION-100 trial expands
Syncromune's SYNC-T therapy shows 80% two-year survival in a Phase 1 metastatic prostate cancer trial. Explore results and Phase 2a plans.
Pharma & Biotech
Pharma & Biotech
Alpheus Medical reports early LDH biomarker findings from 15-patient glioblastoma study
Alpheus Medical reports LDH biomarker findings in 15 glioblastoma patients. The early signal could aid MRI interpretation but needs validation.
Pharma & Biotech
Enhertu cut breast cancer recurrence risk by 53% against T-DM1, but will lung toxicity affect its use?
Enhertu wins EU approval after cutting invasive recurrence or death risk by 53% versus T-DM1. Lung toxicity remains a key consideration.
Pharma & Biotech
Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance?
Frontier's FMC-376 achieved a 56% response rate in 18 evaluable lung cancer patients, including prior KRAS inhibitor users. Can larger trials confirm benefit?
Pharma & Biotech
BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes
BeOne reports new liver and lung cancer responses across three Phase 1 drugs, but dosing, safety and confirmatory evidence will shape development.
Pharma & Biotech
CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery?
CatalYm's visugromab lifted bladder cancer complete responses to 33% versus 8% with nivolumab alone. Can larger trials establish lasting benefit?
Pharma & Biotech
Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial
Bayer's NUBEQA improved four-year metastasis-free survival to 95% in high-risk prostate cancer. Overall survival evidence remains immature.
Features & Analysis
AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer
AstraZeneca PLC (NASDAQ: AZN) and Amgen Inc. (NASDAQ: AMGN) have reported Phase 3 findings showing that IMFINZI (durvalumab) combined with IMDELLTRA (tarlatamab-dlle) reduced the hazard of death by 58% compared with IMFINZI alone as first-line maintenance treatment for extensive-stage small-cell lung cancer. Presented at the European Society for Medical Oncology Congress 2026 on October 24
Pharma & Biotech
Vopimetostat and daraxonrasib show strong tumor responses as Tango Therapeutics targets Phase 3
Tango Therapeutics reports 82% response with vopimetostat and daraxonrasib in pancreatic cancer. Explore the trial results and Phase 3 plans.
Pharma & Biotech
Genialis AI predicts cancer treatment response in small clinical trials using biology-first models
Genialis reports improved cancer response prediction using small patient cohorts and longitudinal AI analysis. Clinical validation remains the next hurdle.